None listed
Conditions
Interventions
None listed
Sponsors
Phytabolites Neutraceuticals Pvt. Ltd
Eligibility
Inclusion criteria
Inclusion criteria: II.Healthy participants having no symptoms of Covid-19 III.Agree to give written consent; for minors, parents/guardians should be ready for participation IV.Voluntarily participation in the clinical trial V.Agreeing to follow study procedures VI.Not participating in any other interventional drug clinical studies before completion of this study VII.Ready to give medical data for assessments
Exclusion criteria
Exclusion criteria: I.People with symptoms of Covid-19 / RT-PCR positive II.Allergic to any ingredient of IP i.e. to Tomato or Rice Bran Oil. III.Where, in the opinion of the investigator, participation in this study will not be in the best interest of the subject, or any other circumstances that prevent the subject from participating in the study safely.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine an increase in the NK Cell Activity in volunteers given a daily dose of 418 microgram/day.Timepoint: 2 Months | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine difference in NK cell activity between: a) days of consumption b) volunteers c) Group 1 and 2 d) Group 1, 2a and 2b e) Group 1 and sub-groups of Group 2 f) Sub-groups of Group 1 and sub-groups of Group 2 based on vaccination, prior Covid history etc. Timepoint: 2 Months | — |
Countries
India
Contacts
Public ContactDr Hrishikesh Rangnekar
Quest Clinical Services
Outcome results
None listed